focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Share News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 22.50
Bid: 22.00
Ask: 23.00
Change: -0.75 (-3.23%)
Spread: 1.00 (4.545%)
Open: 24.25
High: 24.50
Low: 22.50
Prev. Close: 23.25
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Fevertree lowers guidance; DP Poland sales rise

Fri, 15th Jul 2022 11:21

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

----------

AIM - WINNERS

----------

Ncondezi Energy Ltd, up 91% at 1.48 pence, 12-month range 0.004p-1.90p. The Mozambique-based power developer says it has launched a feasibility study for a 300 megawatt solar photovoltaic power plant and battery energy storage system. The study will require four months to be completed and will be funded through available capital after completing the restructuring of the Seritza term loan. The solar project will be located within the Ncondezi concession area, with three sites identified, and have an estimated pre-money net present value between USD60 million and USD65 million.

----------

N4 Pharma PLC, up 21% at 2.85 pence, 12-month range 2.02p-10.43p. In a pre-clinical study of delivery system Nuvec with TNF-alpha, known as Medicines Discovery Catapult, there is clear tumour suppression with 10 micrograms of TNF-alpha loaded into Nuvec, a lower dose than used in earlier studies. Biochemical analysis of blood and tissue samples show that treatment led to an increase in circulating plasma TNF-alpha levels. "We continue to make good progress in understanding how Nuvec can be used in the oncology space," says CEO Nigel Theobald.

----------

Novacyt SA, up 8.5% at 116.99 pence, 12-month range 1.06p-123.77p. The clinical diagnostics firm says its 'exsig' Covid-19 direct real-time PCR test has been approved in the UK under the the UK Health Security Agency's coronavirus test device approvals regulations. The test "removes the need for manual or automated extraction solutions to significantly improve laboratory workflow and reduce costs".

----------

DP Poland Ltd, up 6.9% at 6.20 pence, 12-month range 5.00p-9.00p. The franchise in Poland for Domino's Pizza said system sales were significantly above pre-Covid levels in June. The company saw like-for-like system sales increased by 24% compared to a year ago and by 23% compared to June 2019. Total system sales were up by 21% compared to June 2021 and 15% compared to June 2019. In the first 10 days of July, LFL system sales increased by 33% on a year before.

----------

AIM - LOSERS

----------

Fevertree Drinks PLC, down 27% at 869.50p, 12-month range 804.50p-2,871.00p. In the first half of 2022, the premium tonic water maker posts revenue of GBP160.9 million, up 14% from GBP141.8 million year-on-year. UK sales rise 6% to GBP53.5 million and US sales increase 11% to GBP40.1 million, while total Europe revenue jumps 27% to GBP52.4 million. However, Fevertree now expects earnings before interest, tax, depreciation and amortisation in a range of GBP37.5 million to GBP45 million, down from a prior range of GBP63 million to GBP66 million. In 2021, the company achieved Ebitda of GBP63.0 million. The company flags labour shortages in the US, resulting in greater UK production, which means greater exposure to increasing sea freight rates. In addition, glass availability has become "severely restricted" and industry-wide cost pressures, such as glass, have increased.

----------

Angle PLC, down 12% at 82.20 pence, 12-month range 71.70p-163.75p. The Surrey, England-based medical diagnostics company raises GBP20.1 million through the issue of 25.2 million shares via a placing, retail offer and subscription at a price of 80 pence per share, reflecting a 14% discount to Thursday's closing price at 93.50p. Net proceeds will be used to help its commercialisation plans for its Parsortix system. Now has 260.5 million shares issued overall.

----------

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
24 Jan 2022 09:36

LONDON BROKER RATINGS: Jefferies cuts Berkeley, Barratt and Bellway

LONDON BROKER RATINGS: Jefferies cuts Berkeley, Barratt and Bellway

Read more
21 Jan 2022 10:57

Study shows potential for Angle's Parsortix system in clinical trials

Study shows potential for Angle's Parsortix system in clinical trials

Read more
17 Jan 2022 15:16

Angle says Parsortix system could replace cancer tissue biopsy

Angle says Parsortix system could replace cancer tissue biopsy

Read more
13 Jan 2022 12:06

Angle cancer study delayed as accreditation process for labs starts

Angle cancer study delayed as accreditation process for labs starts

Read more
10 Jan 2022 19:34

TRADING UPDATES: Harvest Minerals sales jump; Quartix earnings to rise

TRADING UPDATES: Harvest Minerals sales jump; Quartix earnings to rise

Read more
15 Nov 2021 14:15

EXECUTIVE CHANGES: Halma hires non-exec; Diurnal names new chair

EXECUTIVE CHANGES: Halma hires non-exec; Diurnal names new chair

Read more
30 Sep 2021 11:07

Angle first-half loss widens, crucial FDA decision expected this year

Angle first-half loss widens, crucial FDA decision expected this year

Read more
27 Sep 2021 17:52

IN BRIEF: Angle notes studies supporting Parsortix system in cancer

IN BRIEF: Angle notes studies supporting Parsortix system in cancer

Read more
23 Sep 2021 15:59

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
22 Sep 2021 21:49

IN BRIEF: Angle's Parsortix used in Spanish study to find cancer

IN BRIEF: Angle's Parsortix used in Spanish study to find cancer

Read more
21 Sep 2021 07:35

IN BRIEF: Angle's Parsortix enables gene analysis in cancer study

IN BRIEF: Angle's Parsortix enables gene analysis in cancer study

Read more
9 Aug 2021 17:08

TRADING UPDATES: Netcall wins new deal; Sareum raises GBP1 million

TRADING UPDATES: Netcall wins new deal; Sareum raises GBP1 million

Read more
28 Jul 2021 18:07

TRADING UPDATES: United Oil & Gas in North Sea sale; Trifast confident

TRADING UPDATES: United Oil & Gas in North Sea sale; Trifast confident

Read more
28 Jul 2021 15:23

Angle agrees pharma services contract with new customer

(Sharecast News) - Liquid biopsy company Angle has agreed a pharma services contract with another new customer, it announced on Wednesday, for its recently-established pharma services business.

Read more
9 Jul 2021 20:19

IN BRIEF: Angle's Parsortix successfully used to harvest cancer cells

IN BRIEF: Angle's Parsortix successfully used to harvest cancer cells

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.